XOMA Corp. (Nasdaq: XOMA) initiated a Phase 2 proof-of-concept study for XOMA 358 in patients with congenital hyperinsulinism sending the stock price up 24 cents to close at $1.31.
XOMA initiates study
October 27, 2015 at 18:49 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.